Verastem, Inc.
Key Metrics
- Previous Close
- $7.30
- 52-Week Range
- $3.43 – $11.25
- Market Cap
- $617.64M
- P/E (TTM)
- —
- EPS (TTM)
- -2.44
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 7.33
- PEG Ratio
- —
- Return on Equity
- -471.16%
- Return on Assets
- -49.59%
- Gross Margin
- 87.64%
- Operating Margin
- -81.62%
- Profit Margin
- -231.59%
- Current Ratio
- 2.25
- Debt/Equity
- 1.69
- Total Debt
- $84.33M
- Free Cash Flow
- $-103.43M
- Revenue Growth
- 1775.40%
- Earnings Growth
- —
- Enterprise Value
- $608.64M
Market Snapshot
About
Verastem, Inc. is a biopharmaceutical company committed to developing and commercializing medicines to improve the lives of patients diagnosed with cancer. The company focuses on treatments targeting critical signaling pathways in cancer cells, with a particular emphasis on therapies for RAS pathway-driven cancers and difficult-to-treat malignancies. Verastem employs precision medicine approaches to identify patients most likely to benefit from its targeted therapies.